Where science and clinical needs meet

SOLVING THE DISCONNECT

We solve the disconnect that exists from discovery to bed-site within the current development trajectory of novel compounds, bridging the valley between in vitro science and the effective treatment of patients by reverse engineering development pathways. 

Working from disease to drug. 

​

The goal of IQ-IDM is to bring promising products forward into efficacy studies. IQ-IDM is underpinned by a team with diverse expertise from advanced virology to business competence.  We excel through in-depth knowledge of the pathogenesis of infectious diseases coupled with clinical know-how from bedside to global clinical trials. 

​

Drugs and other innovative solutions are selected and advanced from the earliest moment in development pathway to Phase 3 utilising the expertise needed at both sides of the spectrum (laboratories through to clinic).

SIMPLIFIED AND TARGETTED INTELLIGENT DESIGN SOLUTIONS

1. Mitigate attrition rate from discovery to clinic and decrease candidate failure rates
   
   

2. Avoid the inefficiencies and expense of a shot gun approach to new chemical entity (NCE) development
   
   

3. Act directly where the crossroads of science and clinical need meet